文献速递糖尿病

以SIGLEC-1为标志、具有强干扰素特征的單核细胞新亚群存在于新发1型糖尿病患者中

A novel subpopulation of monocytes with a strong interferon signature indicated by SIGLEC-1 is present in patients with in recent-onset type 1 diabetes.
PubMed 文献 · Diabetologia · 2024-02-13

研究通过单细胞RNA测序发现早期成人隐匿性自身免疫糖尿病(LADA)患者外周经典单核细胞中新亚群(cluster 4)比例显著升高(11.93% vs 5.93%,p=0.017),该群高表达SIGLEC-1并富集干扰素信号。流式细胞术在LADA、儿童1型糖尿病及NOD小鼠中验证SIGLEC-1+单核细胞升高,且与疾病活动度正相关、与病程负相关;过继转移实验显示该亚群加速NOD小鼠糖尿病发生。

要点

  • 早期LADA患者外周血经典单核细胞新亚群(cluster 4)比例较健康对照显著升高(11.93% vs 5.93%,p=0.017)。
  • 该亚群以SIGLEC-1为标志,具有强干扰素特征,并高表达CC趋化因子受体1/2及T细胞和自然杀伤细胞趋化因子基因。
  • SIGLEC-1+单核细胞比例与LADA患者疾病活动度正相关、与病程负相关,过继转移可加速NOD小鼠糖尿病发生。

核心结论

  • 研究识别出一群SIGLEC-1+单核细胞,可能作为1型糖尿病早期诊断、活动度评估和疗效监测的重要指标,并可能成为预防和治疗1型糖尿病的新靶点。

研究设计与样本

  • 对4例新诊断LADA患者和4例健康对照的外周血单个核细胞进行单细胞RNA测序。
  • 流式细胞术验证队列包括54例LADA、17例成人起病2型糖尿病和26例健康成人,按年龄和性别进行倾向评分匹配。
  • 另一倾向评分匹配队列包括15例儿童1型糖尿病患者和15例健康儿童。
  • 在非肥胖糖尿病(NOD)小鼠外周血和胰腺组织中进行流式细胞术分析,并进行过继转移和清除实验。

主要发现

  • 单细胞RNA测序显示早期LADA患者外周T细胞和单核细胞中上调基因主要富集于干扰素信号通路。
  • LADA患者经典单核细胞新亚群(cluster 4)比例较健康对照显著升高(11.93% vs 5.93%,p=0.017),该群以SIGLEC-1为标志并具有强干扰素特征。
  • SIGLEC-1+单核细胞高表达CC趋化因子受体1或2基因以及T细胞和自然杀伤细胞趋化因子基因,共刺激分子和HLA分子基因水平相对较低。
  • 流式细胞术验证LADA和儿童1型糖尿病患者外周血SIGLEC-1+单核细胞水平高于健康对照和2型糖尿病患者。
  • LADA患者SIGLEC-1+单核细胞比例与疾病活动度正相关、与病程负相关;NOD小鼠外周血该比例6周龄最高(16.88%),胰腺组织12周龄达峰(23.65%)。

临床怎么用

  • 作者认为SIGLEC-1+单核细胞可能作为1型糖尿病早期诊断、活动度评估和疗效监测的重要指标,并可能成为预防和治疗的新靶点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Type 1 diabetes is a T cell-mediated autoimmune disease characterised by pancreatic beta cell destruction. In this study, we explored the pathogenic immune responses in initiation of type 1 diabetes and new immunological targets for type 1 diabetes prevention and treatment. METHODS: We obtained peripheral blood samples from four individuals with newly diagnosed latent autoimmune diabetes in adults (LADA) and from four healthy control participants. Single-cell RNA-sequencing (scRNA-seq) was performed on peripheral blood mononuclear cells to uncover transcriptomic profiles of early LADA. Validation was performed through flow cytometry in a cohort comprising 54 LADA, 17 adult-onset type 2 diabetes, and 26 healthy adults, matched using propensity score matching (PSM) based on age and sex. A similar PSM method matched 15 paediatric type 1 diabetes patients with 15 healthy children. Further flow cytometry analysis was performed in both peripheral blood and pancreatic tissues of non-obese diabetic (NOD) mice. Additionally, cell adoptive transfer and clearance assays were performed in NOD mice to explore the role of this monocyte subset in islet inflammation and onset of type 1 diabetes. RESULTS: The scRNA-seq data showed that upregulated genes in peripheral T cells and monocytes from early-onset LADA patients were primarily enriched in the IFN signalling pathway. A new cluster of classical monocytes (cluster 4) was identified, and the proportion of this cluster was significantly increased in individuals with LADA compared with healthy control individuals (11.93% vs 5.93%, p=0.017) and that exhibited a strong IFN signature marked by SIGLEC-1 (encoding sialoadhesin). These SIGLEC-1+ monocytes expressed high levels of genes encoding C-C chemokine receptors 1 or 2, as well as genes for chemoattractants for T cells and natural killer cells. They also showed relatively low levels of genes for co-stimulatory and HLA molecules. Flow cytometry analysis verified the elevated levels of SIGLEC-1+ monocytes in the peripheral blood of participants with LADA and paediatric type 1 diabetes compared with healthy control participants and those with type 2 diabetes. Interestingly, the proportion of SIGLEC-1+ monocytes positively correlated with disease activity and negatively with disease duration in the LADA patients. In NOD mice, the proportion of SIGLEC-1+ monocytes in the peripheral blood was highest at the age of 6 weeks (16.88%), while the peak occurred at 12 weeks in pancreatic tissues (23.65%). Adoptive transfer experiments revealed a significant acceleration in diabetes onset in the SIGLEC-1+ group compared with the SIGLEC-1- or saline control group. CONCLUSIONS/INTERPRETATION: Our study identified a novel group of SIGLEC-1+ monocytes that may serve as an important indicator for early diagnosis, activity assessment and monitoring of therapeutic efficacy in type 1 diabetes, and may also be a novel target for preventing and treating type 1 diabetes. DATA AVAILABILITY: RNA-seq data have been deposited in the GSA human database ( https://ngdc.cncb.ac.cn/gsa-human/ ) under accession number HRA003649.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Guo M, Guo H, Zhu J, et al. A novel subpopulation of monocytes with a strong interferon signature indicated by SIGLEC-1 is present in patients with in recent-onset type 1 diabetes. Diabetologia. 2024. PMID: 38349399. doi:10.1007/s00125-024-06098-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。